Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

NCT02268526 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

HCMV

Interventions

BIOLOGICAL: CSJ148
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals